



## ASX ANNOUNCEMENT

18 June 2026

### Shares Issued Under Placement – Cleansing Notice

This notice is given by Vitrafy Life Sciences Limited (ASX: VFY) (**Vitrafy** or **Company**) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**).

Vitrafy has today issued 11,538,462 new fully paid ordinary shares (**Placement Shares**) at an issue price of A\$2.60 per Placement Share to certain sophisticated and professional investors under the institutional placement announced by the Company on Friday, 12 June 2026 (**Placement**).

The Placement is being conducted in conjunction with a non-underwritten share purchase plan, also announced by the Company on Friday, 12 June 2026.

In relation to the Placement, the Company advises that:

1. the Placement Shares the subject of this notice were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
2. As at the date of this notice, Vitrafy has complied with:
  - a) the provisions of Chapter 2M of the Corporations Act as they apply to Vitrafy; and
  - b) section 674 and 674A of the Corporations Act as it applies to Vitrafy.
3. As at the date of this notice, there is no “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be set out in this notice.

In accordance with paragraph 7(f) of the *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547*, this notice also serves as a cleansing notice for the Company’s share purchase plan announced on Friday, 12 June 2026.

**### ENDS ###**

This announcement is authorised by the Board of Vitrafy Life Sciences Limited.

#### For further information contact:

Tim Sharpe  
Vice President of Strategy & Corporate Development  
[investors@vitrafy.com](mailto:investors@vitrafy.com)



## About Vitrafy

Vitrafy has developed a proprietary cryopreservation ecosystem including the Guardian cryopreservation freezing unit, and Lifechain™, a cloud-based software platform, to offer a complete cryopreservation solution. The Vitrafy ecosystem delivers a new standard of cryopreservation of biomaterial quality, empowering industries to retain the integrity of sensitive biological samples throughout the collection, storage and delivery process. Vitrafy's innovative approach combines cutting-edge technology and seamless software integration to optimise cryopreservation, ensuring reliability and efficiency in maintaining valuable biological assets.

Vitrafy is headquartered in Melbourne, Australia and is listed on the Australian Securities Exchange (ASX: VFY).

For more information visit [vitrafy.com](http://vitrafy.com).